HER2-positive breast cancer has an unfavorable prognosis, with an amplified risk of relapse and a more aggressive course of the disease, which is shown by the 44% of relapses after the first line of treatment with monoclonal antibodies. The gene discussed is ERBB2; the disease is breast carcinoma.